These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35301436)

  • 1. Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.
    Woof VG; Lee RJ; Lorigan P; French DP
    Br J Cancer; 2022 Jun; 126(10):1450-1456. PubMed ID: 35301436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumour DNA in Melanoma-Clinic Ready?
    Tivey A; Britton F; Scott JA; Rothwell D; Lorigan P; Lee R
    Curr Oncol Rep; 2022 Mar; 24(3):363-373. PubMed ID: 35133615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of metastases using circulating tumour DNA in uveal melanoma.
    Beasley AB; de Bruyn DP; Calapre L; Al-Ogaili Z; Isaacs TW; Bentel J; Reid AL; Dwarkasing RS; Pereira MR; Khattak MA; Meniawy TM; Millward M; Brosens E; de Klein A; Chen FK; Kiliҫ E; Gray ES
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14953-14963. PubMed ID: 37608028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
    Brunsgaard EK; Bowles TL; Asare EA; Grossmann K; Boucher KM; Grossmann A; Jackson JA; Wada DA; Rathore R; Budde G; Grandemange A; Hyngstrom JR
    Melanoma Res; 2023 Jun; 33(3):184-191. PubMed ID: 37040662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
    Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.
    Relton A; Collins A; Guttery DS; Gorsia DN; McDermott HJ; Moss EL
    Eur J Cancer Care (Engl); 2021 Jul; 30(4):e13429. PubMed ID: 33616269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
    Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
    Garcia-Murillas I; Chopra N; Comino-Méndez I; Beaney M; Tovey H; Cutts RJ; Swift C; Kriplani D; Afentakis M; Hrebien S; Walsh-Crestani G; Barry P; Johnston SRD; Ring A; Bliss J; Russell S; Evans A; Skene A; Wheatley D; Dowsett M; Smith IE; Turner NC
    JAMA Oncol; 2019 Oct; 5(10):1473-1478. PubMed ID: 31369045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
    Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
    Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
    Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
    J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
    Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
    Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Hou JY; Chapman JS; Kalashnikova E; Pierson W; Smith-McCune K; Pineda G; Vattakalam RM; Ross A; Mills M; Suarez CJ; Davis T; Edwards R; Boisen M; Sawyer S; Wu HT; Dashner S; Aushev VN; George GV; Malhotra M; Zimmermann B; Sethi H; ElNaggar AC; Aleshin A; Ford JM
    Gynecol Oncol; 2022 Nov; 167(2):334-341. PubMed ID: 36117009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.
    Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
    Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.